Association between Val/Leu(247) polymorphism of apolipoprotein H and cerebral infarction in a Chinese population.
BACKGROUND
Antiphospholipid antibodies (aPL) are considered to be a cause of an acquired hypercoagulable state leading to cerebral infarction (CI). Apolipoprtein H (apoH) is an important target antigen for aPL and thus apoH polymorphisms may influence aPL production and the development of CI. The purpose of this study was to identify associations between the Val/Leu(247) polymorphism of apoH gene and CI in a Chinese cohort.


METHODS
This study comprised 130 CI patients and 100 healthy control subjects. Polymorphism assignment was determined by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and DNA sequencing. The presence of aPL was detected by ELISA utilizing irradiated ELISA plates.


RESULTS
Our results demonstrated an association between the Val/Leu(247) polymorphism of apoH gene and aPL in CI patients. The frequency of V allele was significantly higher in aPL-positive CI patients compared with control group (chi(2) = 6.864, P < 0.05). VL genotype frequency was also significantly higher in aPL-positive CI group compared with control group (chi(2) = 13.879, P < 0.05) and aPL-negative CI group (chi(2) = 5.567, P < 0.05).


CONCLUSIONS
The Val(247) allele of apoH gene is significantly associated with the presence of aPL in Chinese patients with CI.
Xia
Jian
J
Institute of Neurology, Xiangya Hospital, Central South University, Hunan, People's Republic of China. xiajian1216@sina.com
Yuan
Mei
M
Xu
Hong-wei
HW
Zhang
Le
L
Du
Xiao-ping
XP
Liu
Yun-hai
YH
Yang
Qi-dong
QD
D000328:Adult; D000368:Aged; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D044466:Asian People; D016022:Case-Control Studies; D002544:Cerebral Infarction / Q000097:blood / Q000208:ethnology / Q000235:genetics*; D002681:China / Q000453:epidemiology; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012307:Risk Factors; D053482:beta 2-Glycoprotein I / Q000235:genetics*
D017152:Antibodies, Antiphospholipid; D053482:beta 2-Glycoprotein I
Neurology. 2001;57(5 Suppl 2):S24-30
11552051
Ann Hum Genet. 2004 Jul;68(Pt 4):285-99
15225155
J Exp Med. 1994 Feb 1;179(2):457-62
7507506
Arthritis Rheum. 2005 Jan;52(1):212-8
15641049
Hum Genet. 1997 Jul;100(1):57-62
9225969
Thromb Haemost. 1998 Nov;80(5):791-7
9843173
Lupus. 2006;15(4):218-22
16686261
Autoimmun Rev. 2007 Sep;6(8):547-52
17854747
Cerebrovasc Dis. 2005;20 Suppl 2:75-83
16327256
Neurology. 1993 Oct;43(10):2069-73
8413969
Cerebrovasc Dis. 2002;13 Suppl 1:7-11
11803181
Br J Haematol. 2003 Mar;120(6):1066-72
12648080
Neurology. 2001 Apr 24;56(8):997-1008
11339244
Hokkaido Igaku Zasshi. 2001 Sep;76(5):289-98
11593753
Thromb Haemost. 1995 Oct;74(4):1185-90
8560433
Thromb Res. 2004;114(5-6):489-99
15507283
Arthritis Rheum. 2003 Feb;48(2):471-4
12571857
Arthritis Rheum. 1999 Aug;42(8):1655-61
10446865
Cerebrovasc Dis. 2005;20 Suppl 2:53-67
16327254
Rheumatology (Oxford). 1999 Aug;38(8):721-3
10501418
Rom J Intern Med. 2007;45(2):201-4
18333375
Eur J Biochem. 2003 Jan;270(2):230-8
12605674
Clin Rheumatol. 2007 Mar;26(3):302-7
16724168
Eur J Biochem. 1999 Jan;259(1-2):435-40
9914524
Prostaglandins Other Lipid Mediat. 1999 Jul;57(5-6):351-9
10480489
Intern Med. 2006;45(17):1017-8
17016003
Lupus. 2005;14(6):440-4
16038107